Abivax jumps after data address obefazimod safety concerns

Abivax SA

30/06/2026 08:23

** Shares in Abivax ABVX.PA jump 23% after the French biotech company addressed safety concerns over its experimental ulcerative colitis drug
** The company published additional data from its obefazimod trial showing that the drug helped harder-to-treat patient groups achieve remission
** Abivax added that the expanded safety dataset showed cancer rates were in line with those typically seen in ulcerative colitis patients
** Kempen says that, now that the malignancy overhang has been addressed, the focus will shift to obefazimod's "best-in-class" efficacy profile
** U.S.-listed shares of the Paris-based company soared 26.4% in extended trading overnight
** Shares in Abivax had sunk earlier this month after publishing its first late-stage trial data, as investors focused on cancer cases reported in patients taking the higher dose, although investigators considered the cases unrelated to treatment
** Today's rally nearly erased the losses recorded earlier this month
     

(Reporting by Lucie Barbier)
((Email: lucie.barbier@thomsonreuters.com))